SCHEMBL3846314

SCHEMBL3846314

CC(C)(C)C(O)C#CC(F)(F)Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3844100 0.76
SCHEMBL14767317 0.75
SCHEMBL15691229 0.75
SCHEMBL21880230 0.73
SCHEMBL21878549 0.70
SCHEMBL19262300 0.70
SCHEMBL21880240 0.69
SCHEMBL21878553 0.67 PGK1 (0.31)
SCHEMBL487155 0.64
SCHEMBL21877566 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111385-B1 Substituted alkine derivatives as anti-cancer agents UNIV LOUISVILLE RES FOUND (US) 2014-11-12 EP claimed
US-8703829-B2 Therapeutic compounds UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2014-04-22 US claimed
US-8207381-B2 1-Bromo-1,1-difluoro-non-2-yn-4-ol; 6-Bromo-6,6-difluoro-2,2-dimethyl-hex-4-yn-3-ol; anticarcinogenic, -tumor, -metastasic agents; enzyme inhibitors of modification methylases; myelodysplastic syndrome, leukemia, a solid tumor, schizophrenia, sickle cell disease, or lupus; breast, colon, brain cancers UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2012-06-26 US claimed
EP-2111385-A2 SUBSTITUTED ALKINE DERIVATIVES AS ANTI-CANCER AGENTS University Of Louisville Research Foundation, Inc. (US) 2009-10-28 EP claimed
WO-2008098077-A2 SUBSTITUTED ALKINE DERIVATIVES AS ANTI-CANCER AGENTS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2008-08-14 WO claimed
US-11679098-B2 Methods for treating diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2023-06-20 US disclosed
US-11679098-B2 Methods for treating diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2023-06-20 US disclosed
US-20200108050-A1 METHODS FOR TREATING DISEASES UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2020-04-09 US disclosed
EP-2111385-B1 Substituted alkine derivatives as anti-cancer agents UNIV LOUISVILLE RES FOUND (US) 2014-11-12 EP disclosed
US-8703829-B2 Therapeutic compounds UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2014-04-22 US disclosed
EP-2567950-A1 Substituted alkine derivatives as anti-cancer agents University Of Louisville Research Foundation, Inc. (US) 2013-03-13 EP disclosed
US-20120329866-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2012-12-27 US disclosed
US-8207381-B2 1-Bromo-1,1-difluoro-non-2-yn-4-ol; 6-Bromo-6,6-difluoro-2,2-dimethyl-hex-4-yn-3-ol; anticarcinogenic, -tumor, -metastasic agents; enzyme inhibitors of modification methylases; myelodysplastic syndrome, leukemia, a solid tumor, schizophrenia, sickle cell disease, or lupus; breast, colon, brain cancers UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2012-06-26 US disclosed
EP-2111385-A2 SUBSTITUTED ALKINE DERIVATIVES AS ANTI-CANCER AGENTS University Of Louisville Research Foundation, Inc. (US) 2009-10-28 EP disclosed
WO-2008098077-A2 SUBSTITUTED ALKINE DERIVATIVES AS ANTI-CANCER AGENTS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2008-08-14 WO disclosed
US-20080188570-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2008-08-07 US disclosed